Skip to main content
Top

09-05-2024 | Crohn's Disease | Hollow Organ GI

Prospective characterization of intestinal MRI intravoxel incoherent motion in pediatric and young adult patients with newly diagnosed small bowel Crohn’s disease

Authors: Vinicius de Padua V. Alves, Neeraja Mahalingam, Jean A. Tkach, Alexander J. Towbin, Rebecca Imbus, Lee A. Denson, Jonathan R. Dillman

Published in: Abdominal Radiology

Login to get access

Abstract

Background

MRI diffusion-weighted imaging (DWI) is commonly used in MR enterography protocols for assessment of intestinal inflammation in patients with Crohn’s disease. The intravoxel incoherent motion (IVIM) approach to DWI has been proposed as a more objective approach, providing quantitative parameters that reflect water diffusivity (D), blood flow (D*), and perfusion fraction (f).

Purpose

We aimed to determine if DWI-IVIM metrics from the terminal ileum in patients with newly diagnosed Crohn’s disease differ from healthy participants and change in response to biologic medical therapy.

Methods

In this prospective case–control study, 20 consecutive pediatric patients (mean age = 14 years ± 2 [SD]; eight females) with newly diagnosed ileal Crohn’s disease and 15 pediatric healthy participants (mean age = 18 years ± 4 [SD]; eight females) underwent research MRI examinations of the small bowel between 12/2018 and 10/2021. Participants with Crohn's disease underwent MR studies at baseline, 6 weeks, and 6 months following initiation of anti-TNF-alpha therapy, whereas control participants underwent one research MRI examination. The MRI protocol included a DWI-IVIM sequence with nine b-values and the IVIM parameters (D, D*, and f) were extracted. Unpaired t-tests and mixed-effects models were used for analyses.

Results

Mean IVIM D (P < 0.001), D* (P = 0.004), and f (P = 0.001) metrics were lower for Crohn’s patients at the time of diagnosis compared to healthy participants. Mean IVIM f value increased over time in response to medical therapy (mean f at baseline, 22% ± 6%; 6 weeks, 25% ± 7%; 6 months, 29% ± 10%; P = 0.016). Mean IVIM D* value increased over time in response to treatment (mean D* at baseline, 10.9 ± 3.0 × 10−3 mm2/s; 6 weeks, 11.8 ± 2.8 × 10−3 mm2/s; 6 months, 13.3 ± 3.3 × 10−3 mm2/s; P = 0.047), while there was no significant change in mean IVIM D value (P = 0.10).

Conclusion

MRI DWI-IVIM metrics in patients with ileal Crohn’s disease change over time in response to biological therapy and help discriminate these patients from healthy participants.

Graphical abstract

Appendix
Available only for authorised users
Literature
1.
go back to reference S. Alatab et al., “The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017,” The Lancet Gastroenterology and Hepatology, vol. 5, no. 1, pp. 17–30, 2020, https://doi.org/10.1016/S2468-1253(19)30333-4.CrossRef S. Alatab et al., “The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017,” The Lancet Gastroenterology and Hepatology, vol. 5, no. 1, pp. 17–30, 2020, https://​doi.​org/​10.​1016/​S2468-1253(19)30333-4.CrossRef
28.
go back to reference J. R. Dillman, J. A. Tkach, R. Imbus, A. J. Towbin, and L. A. Denson, “MRI-Based Characterization of Intestinal Motility in Children and Young Adults With Newly Diagnosed Ileal Crohn Disease Treated by Biologic Therapy: A Controlled Prospective Study,” American Journal of Roentgenology, vol. 219, no. 4, pp. 655–664, 2022, https://doi.org/10.2214/AJR.22.27792.CrossRefPubMed J. R. Dillman, J. A. Tkach, R. Imbus, A. J. Towbin, and L. A. Denson, “MRI-Based Characterization of Intestinal Motility in Children and Young Adults With Newly Diagnosed Ileal Crohn Disease Treated by Biologic Therapy: A Controlled Prospective Study,” American Journal of Roentgenology, vol. 219, no. 4, pp. 655–664, 2022, https://​doi.​org/​10.​2214/​AJR.​22.​27792.CrossRefPubMed
35.
Metadata
Title
Prospective characterization of intestinal MRI intravoxel incoherent motion in pediatric and young adult patients with newly diagnosed small bowel Crohn’s disease
Authors
Vinicius de Padua V. Alves
Neeraja Mahalingam
Jean A. Tkach
Alexander J. Towbin
Rebecca Imbus
Lee A. Denson
Jonathan R. Dillman
Publication date
09-05-2024
Publisher
Springer US
Published in
Abdominal Radiology
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-024-04318-4
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare
Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare